3Q Revenues: $11.6 billion (-3%)
3Q Earnings: $2.1 billion (-23%)
YTD Revenues: $34.0 billion (+6%)
YTD Earnings: $6.0 billion (+6%)
Comments: Sales lost to generic competition were $576.0 million in the quarter, primarily due to generic competition for Eloxatin in the U.S. Lantus sales were up 21% to $1.6 billion, driven by U.S. sales (+22%) and Emerging Markets (+32%). New Genzyme sales were up 23%, driven by the Fabrazyme recovery. Vaccines sales were $1.9 billion (+1%). The impact of the Plavix and Avapro loss of exclusivity in the U.S. was $602.9 million at CER.